Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophages Authors: Wattanased Jarisarapurin, Khwandow Kunchana, Onnicha Srisopar, Kitiyarat Bunsoong, Sittiruk Roytrakul, Sarawut Kumphune Published: 2026 ABSTRACT AbstractInflammation is a crucial defence mechanism against infections and harmful stimuli. However, uncontrolled inflammation can lead to low-grade inflammatory conditions that disrupt tissues and systemic function. Anti-inflammatories relieve symptoms. However, it can cause side effects and lack targeted control. These limitations are addressed by “peptide-based therapeutics.” The secretory leukocyte protease inhibitor (SLPI) has anti-inflammatory effects. However, SLPI has a short half-life and low cellular uptake. Using short peptides is a promising therapeutic strategy due to their small size, high effectiveness, and low immunogenicity. This research investigates the anti-inflammatory effect of SLPI-derived short peptides (SDSPs). SLPI was enzymatically digested in silico to produce SDSPs. The physiological properties of SDSPs and their anti-inflammatory activities in an LPS-induced RAW 264.7 cell inflammatory model were examined. Digested fragments, including 11 from pepsin (P1-11) and 9 from trypsin (T1-T9) digestion, plus the N-terminal fragment, were obtained. SDSPs are diverse physiological properties, and some are anti-inflammatory peptides (AIPs). Determination in the LPS-induced macrophage inflammation model found four potential SDSPs, specifically T6, T7, T8, and P7, exhibit anti-inflammatory properties by reducing excessive ROS generation and the activation of the MAPK/NF-κB pathway, similar to SLPI. This study identifies possible candidates for anti-inflammatory medicines warranting further investigation in in vivo and clinical trials for inflammation-related disorders.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-45716-6.Keywords: Bioactive short peptide, Anti-inflammatory peptide, Cytokine storm, Antioxidant peptides, Therapeutic peptideSubject terms: Diseases, Drug discovery, Immunology Introduction Prolonged inflammatory responses not only disrupt normal physiological balance but also impair vital organs, including the liver, lungs, kidneys, and heart, resulting in systemic dysfunction. These are linked to the onset and advancement of numerous non-communicable diseases (NCDs) including diabetes, cardiovascular diseases, cancer, and neurodegenerative disorders1. A key driver of these processes is the activity of immune cells. Among them, activation of monocytes and/or macrophages are crucial steps in inflammatory events, which play a crucial role as sentinels of the innate immune system. Derived from circulating monocytes, they reside in tissues where they constantly survey the microenvironment for invading pathogens or harmful signals2. Through pattern-recognition receptors (PRRs), such as toll-like receptors (TLRs), macrophages detect microbial components and cellular damage, triggering the release of cytokines, chemokines, and other mediators that coordinate the inflammatory response3. A well-known trigger of macrophage activation is lipopolysaccharide (LPS), a component of bacterial cell walls. LPS stimulation sets off a chain of intracellular events, generating reactive oxygen species (ROS) and activating signaling pathways like mitogen-activated protein kinases (MAPKs) and triggering transcription factor NF-κB translocation into the nucleus4. These pathways increase the production of pro-inflammatory genes and promote the release of cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α)5. When macrophage activation becomes excessive or prolonged, it can result in uncontrolled cytokine release, sometimes referred to as a “cytokine storm”, and contribute to lingering post-infection inflammation6. This persistent response can contribute to the development of a variety of inflammatory diseases and disrupt tissue homeostasis over time7. The main goals of current treatments for inflammatory conditions are to reduce symptoms and prevent tissue damage. Anti-inflammatory medications can alleviate pain and injury; however, these approaches lack targeted inflammation control and may induce side effects such as gastric ulcers, significant cardiovascular complications, hypertension, acute renal failure, and exacerbation of pre-existing heart failure8. These constraints can be overcome using “peptide-based therapeutics,” which exhibit low immunogenicity and minimal side effects9. The secretory leukocyte protease inhibitor (SLPI) is a 11.7 kDa cationic secreted protein, comprised of 107 amino acids. SLPI inhibits inflammatory serine proteases like trypsin, chymotrypsin, and others10. It also acts as an antimicrobial peptide (AMPs) in that it can directly eliminate bacteria11 and also disrupts human immunodeficiency virus 1 (HIV-1)12. SLPI exerts its anti-inflammatory effects by reducing the production of reactive oxygen species (ROS)10,13, which subsequently decreases the levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, via targeting NF-κB10. These mechanisms are key to the anti-inflammatory action of SLPI, which has therapeutic anti-inflammatory potential, which might benefit to reduce cytokine storms and post-infection inflammation. However, preclinical investigations show that recombinant human SLPI has a short half-life, which limits its use as a therapeutic agent14. SLPI can be destroyed by other proteases and low cellular intake, limiting its therapeutic usefulness. Improvements to SLPI therapeutic usage are needed. In the past decade, there have been significant advancements in the production, modification, and assessment of peptide therapeutics15. Short peptides yield vital biological information that elucidates the intricate structure of living organisms. These entities possess unique characteristics and have significant potential to enhance the development of biotherapies15. Bioactive peptides imitate natural pathways and possess notable efficacy which their small protein fragments and have several therapeutic benefits, including small size, capacity to permeate cellular membranes, high activity, specificity, affinity, stability, and minimal immunogenicity16,17. Thus, employing novel SLPI-derived short peptides (SDSPs) to improve SLPI stability and effectiveness may minimize inflammation and post-infection inflammation-related diseases. The roles and effects of SDSPs on anti-inflammation have not been investigated. This research aims to examine the anti-inflammatory effects and the underlying mechanisms of SDSPs utilizing an LPS-induced RAW 264.7 macrophage model. SDSPs were predicted by in silico digestion of pepsin and trypsin. Obtained SDSPs predicted the physicochemical properties using in silico analysis, and the validation test was examined in an in vitro experiment. The study evaluates cytotoxicity via MTT assays, quantifies ROS production using DCFH-DA, measures proinflammatory cytokine release through ELISA, and investigates essential signaling pathways through Western blotting. Furthermore, toxicity assessments in human-derived vital organ cell lines, such as EA.hy926, AC16, BEAS-2B, HepG2, HEK293, and BJ5ta, are performed on SDSP that demonstrate significant anti-inflammatory effects. These studies will clarify the therapeutic potential of SDSPs as targeted anti-inflammatory agents. Results Physicochemical characterization of SDSP fragments Peptides generated from in silico cleavage of the full-length SDSP using pepsin and trypsin exhibited diverse physicochemical characteristics. Only fragments longer than five amino acids were included for this study. Because fragments such as dipeptides, tripeptides, and tetrapeptides are generally considered unsuitable for evaluation in drug discovery due to their suboptimal pharmacological characteristics, substantial instability, and insufficient specificity. This ensures a substantial diversity of side chains, facilitating the formation of stable molecular interactions and indicating unique functional motifs. A total of 21 peptide fragments were obtained from N-terminal region and cleavage of the full-length SDSP, including 11 pepsin-derived (P-stain) and 9 trypsin-derived (T-stain) peptides. Table 1 shows a summary of the physical and chemical properties of SLPI and these peptide fragments. The full-length SLPI consists of 132 amino acids with a molecular mass of 14,326.09 g/mol. In contrast SDSPs significantly smaller, length from 6 to 51 amino acids (508.6 and 5441.564 g/mol). The Wimley–White whole-residue hydrophobicity values of SLPI was 26.05, reflecting its total hydrophobic bulk. SDSP showed variation in hydrophobic ranged from − 2.34 to 9.31. Among the fragments, P4, P7, and P11 showed the highest positive values, while T1 and T8 showed lowest. The high hydrophobic values, indicating high density of hydrophobic residues that may facilitate membrane interaction. Table 1In silico physicochemical properties of the SDSPs.SDSPsPeptide length (aa)Peptide sequenceMass (g/mol)The Wimley-White whole-residue hydrophobicityProtein-binding Potential (Boman index) (kcal/mol)Theoretical pIAliphatic indexGrand average of hydropathicity (GRAVY)Net charge (pH7.4)Instability indexHaemolytic PredictionAnti-Inflammatory Peptides (AIPs) predictionP15MKSSG508.5921.031.818.50−0.80.9946.521%0.3651P212LAPWAVEGSGKS1201.3421.740.19673.33−0.058−0.013.220%0.3744P314FKAGVCPPKKSAQC1463.7783.390.819.3935−0.2862.7820.680%0.4000P428RYKKPECQSDWQCPGKKRCCPDTCGIKC3261.8549.312.938.8913.93−1.2793.3644.710%0.6558P524LDPVDTPNPTRRKPGKCPVTYGQC2643.047.912.548.8640.42−1.0751.7826.90%0.5791P66LNPPNF700.7940.050.895.5265−0.6−0.0110.580%0.3744P728CEMDGQCKRDLKCCMGMCGKSCVSPVKA3011.7098.191.478.3338.21−0.1361.3654.661%0.6674P89WAVEGSGK832.9081.550.71648.75−0.4875−0.01−20.650%0.3884P98KKPECQSD934.0316.154.286.180−2.275−0.11121.481%0.5093P1017QCPGKKRCCPDTCGIKC1840.2615.142.078.7822.94−0.6412.4718.551%0.7023P1120LDPVDTPNPTRRKPGKCPVT2191.5368.52.879.3148.5−1.1551.8938.30%0.5488T126SSGLFPFLVLLALGTLAPWAVEGSGK2631.112−2.34−1.155.72123.851−0.0125.8350%0.4767T27AGVCPPKK798.9982.890.379.3248.75−0.36251.8956.98%0.4395T36SAQCLR676.7960.892.647.9681.67−0.1170.8959.979%0.5023T413KPECQSDWQCPGK1505.6895.12.716.050−1.7−0.2281.081%0.4884T59CCPDTCGIK939.1431.790.795.8243.330.211−0.32−13.661%0.4930T612CLDPVDTPNPTR1327.4844.592.824.2156.67−0.892−1.1113.820%0.5140T724CPVTYGQCLMLNPPNFCEMDGQCK2692.173.210.814.3744.58−0.171−1.4320.860%0.5186T88CCMGMCGK832.122−0.17−0.67.9600.8250.6838.891%0.5488T97SCVSPVK718.8691.60.427.9482.860.54280.89130.541%0.5140N-terminal51MKSSGLFPFLVLLALGTLAPWAVEGSGKSFKAGVCPPKKSAQCLRYKKPEC5441.5645.460.299.6780.390.1335.6737.8235%0.5256SLPI132MKSSGLFPFLVLLALGTLAPWAVEGSGKSFKAGVCPPKKSA14326.0926.051.259.1155.38−0.30510.3040.4053%0.5814QCLRYKKPECQSDWQCPGKKRCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYGQCLMLNPPNFCEMDGQCKRDLKCCMGMCGKSCVSPVKA In silico physicochemical properties of the SDSPs. The Boman index (or protein-binding potential) was analysed to predict the functional mechanism of the SDSPs. This index estimates a peptide’s tendency toward protein-protein interaction (PPI), with higher (more positive) values favouring receptor binding over membrane interaction. The full-length SLPI exhibited a Boman index of 1.25 kcal/mol, indicating a moderate potential for protein binding. Most of SDSPs exhibited positive Boman index values, ranging from 0.19 to 4.28 kcal/mol, with P9 showing the highest. This distribution indicates that the principal functional mechanism of these peptides involves specific receptor binding or other protein-protein interactions, rather than membrane disruption. Those of the sequences that had negative Boman index values were T1 and T8, which had values of − 1.15 and − 0.6 kcal/mol, respectively. Peptides that are more likely to interact with membranes typically exhibit negative values, which are linked to higher hydrophobicity. Theoretical isoelectric points (pI) of SLPI and SDSPs ranged from 4.21 to 9.67, indicating a mixture of acidic and basic sequences. Among the peptides analysed, T6 and T7 exhibited the lowest pI values (4.21 and 4.37), indicating strong acidic character, while N-terminal, P3, P11, T2, and SLPI showed the highest pI values (9.67, 9.39, 9.31, 9.32, and 9.11), suggesting strong basic properties. The aliphatic index of the analysed peptides ranged from 0 to 123.85, indicating considerable variability in the content of aliphatic (Ala, Val, Leu, Ile) residues. SLPI and Most SDSPs had moderate aliphatic indices (20–80), while T1 had the highest value (123.85), reflecting a highly aliphatic, potentially more thermostable peptide. Several peptides (e.g., P1, P9, T4, and T8) were indexed to 0, indicating little to no aliphatic content. The GRAVY values of the SLPI and SDSPs ranged from − 2.275 to 1, indicating a wide spectrum of hydrophobicity. SLPI and most peptides had negative values, suggesting they are generally hydrophilic, whereas a few peptides (T1, T5, T8, and T9) showed positive GRAVY values (1, 0.211, 0.825, and 0.5428), indicating more hydrophobic character. The predicted net charge of the SDSPs at pH 7.4 ranged from − 1.43 to 5.67. Most peptides had a slightly positive or near-neutral charge (− 0.32 to 1.0), while a few peptides, such as N-terminal (5.67), P4 (3.36) and P3 (2.78), were more strongly positive. Conversely, T7 (− 1.43) and T6 (− 1.11) carried the most negative charges. In contrast, the full-length SLPI carries a strong net positive charge of + 10.30, making it highly cationic. This high positive charge can facilitate electrostatic interactions with negatively charged components like cell or microbial membranes. The instability index predicts the stability (< 40) and instability (> 40) of peptides, which ranged widely from − 20.65 to 130.54. SLPI (40.40) and most SDSPs were moderately stable, but T9 (130.54), P9 (121.48), and T4 (81.08), were severely unstable. Some SDSPs had negative values, such as P8 (− 20.65) and T5 (− 13.66), suggesting high stability. Haemolytic activity predictions indicated that most SDSPs are non-haemolytic, with values close to 0–1%, suggesting minimal potential for red blood cell lysis. A few peptides showed higher predicted haemolytic potential, notably SLPI (53%), T1 (50%), N-terminal (35%), T2 (8%), and T3 (9%), indicating caution if used at high concentrations. The anti-inflammation peptide (AIP) prediction scores for the SDSPs ranged from 0.3651 to 0.7023, reflecting variable potential for anti-inflammatory activity. Most SDSPs had moderate predicted anti-inflammatory activity, with probabilities near the threshold of 0.5, indicating low to moderate confidence. Some SDSPs-derived pepsin, including P4 (0.6558), P7 (0.6674), and P10 (0.7023), showed higher predicted activity than SLPI (0.5814) while the T group, such as T6 (0.5140), T7 (0.5186), T8 (0.5488), and T9 (0.5140), showed higher than 0.5, suggesting stronger potential to act as anti-inflammatory peptides. The predicted 3D structures from the peptide sequence are shown in Fig. 1, illustrating their secondary structural elements. Predicted 3D structures of SDSPs. Effect of LPS on the RAW 264.7 cell inflammatory model This study optimizes the inflammatory model utilizing RAW 264.7 macrophage cells. Figure 2a illustrates the morphological alterations of cells following treatment or lack thereof with different doses of LPS at 0.001, 0.01, 0.1, 1, 10, and 100 µg/mL. Following induction, we observed the differentiation of monocytes into M1 macrophages based on morphology in a dose-dependent manner. Upon assessing the toxicity of LPS on cells, we determined that it exhibited no toxicity at any dosage. However, all concentrations significantly enhanced cell metabolic activity to 140.92 ± 0.95%, 135.97 ± 1.75%, 128.77 ± 1.19%, 113.25 ± 0.94%, 117.29 ± 0.14%, and 117.14 ± 0.15% compared to the control (100%), with p < 0.001, respectively (Fig. 2b). Releases of proinflammatory cytokines using an ELISA kit found increases of both TNF-⍺ and IL-6. Induction of macrophages by various concentrations at 0.001, 0.01, 0.1, 1, 10, and 100 µg/mL found increases in the levels of TNF-⍺ to 8400.28 ± 92.30, 9383.57 ± 338.43, 12455.93 ± 592.92, 13855.11 ± 117.01, 13540.06 ± 226.70, and 12538.63 ± 825.06 pg/mL, respectively, when compared to vehicle control (446.04 ± 22.34 pg/mL) at p < 0.01 (Fig. 2c). Likewise, IL-6 that was treated with LPS at concentrations of 0.1, 1, 10, and 100 µg/mL showed a significant increase in IL-6 levels to 240.18 ± 31.92, 1889.28 ± 290.80, 2298.00 ± 115.69, 2527.01 ± 224.65, and 12365.38 ± 341.32 when compared to the control, 0.001, and 0.01 µg/mL, which did not detect the level of IL-6 (Fig. 2d). Thus, the LPS had no toxic effect on cells and increased cell viability or mitochondrial activity because of the differentiation effect. Therefore, 1 µg/mL is validated for its non-toxic and steady inflammatory induction. LPS-induced cytotoxicity and inflammatory responses in RAW 264.7 cells. (a) Morphological changes observed under light microscopy at 100x magnification. (b) Cell viability was assessed by MTT assay. (c) Levels of TNF-α after LPS exposure. (d) Levels of IL-6 after LPS exposure. *** p < 0.001 compared to vehicle-control cells. Determination of cytotoxicity of SDSPs on RAW 264.7 cells Various concentrations of SDSPs were applied to the cells for 24 h to examine their toxicity using the MTT assay. Figure 3a shows the cytotoxicity of the P groups, Fig. 3b shows the cytotoxicity of the T groups, and Fig. 3c shows the cytotoxicity heat map of all SDSPs. Cytotoxicity analysis revealed that all SDSPs exhibited no detectable toxicity toward RAW 264.7 cells at concentrations less than 1 µg/mL, showing no significant difference in cell viability compared to the vehicle control (p > 0.05). However, at a concentration of 10 µg/mL, P4, T1, T7, and T8 showed a significant decrease in cell viability to 61.27 ± 2.48%, 57.95 ± 1.73%, 43.06 ± 0.91%, and 43.12 ± 0.86%, respectively (p < 0.001). The full-length SLPI was included in this study because it previously demonstrated significant anti-inflammatory activity, and its cytotoxicity assessment was necessary to confirm cellular safety. In contrast, the N-terminal fragment has not yet been experimentally validated. Both forms exhibited no cytotoxicity at any tested concentration, showing no significant difference from the vehicle control (p > 0.05). Based on these results, we further investigate the anti-inflammatory effect of SDSPs at non-cytotoxic doses, excluding any toxic doses. Cytotoxic effects of SDSPs on RAW264.7 cells. (a) Cytotoxicity of peptides generated by pepsin digestion (P groups). (b) Cytotoxicity of peptides generated by trypsin digestion (T groups). (c) Heat map of SDSPs cytotoxicity. *** p < 0.001 compared to vehicle-control cells. Effect of SDSPs on pro-inflammatory TNF-ɑ and IL-6 releases To evaluate the anti-inflammatory activity of SDSPs, the levels of IL-6 and TNF-α were quantified in LPS-stimulated RAW 264.7 macrophages following the determination of cytokine concentration by an ELISA kit. Following the optimization model, LPS stimulation markedly increased the secretion of IL-6 and TNF-α compared with the unstimulated control (p < 0.001). Among SDSPs derived from pepsin digestion, P5 significantly reduced TNF-α release at 10 µg/mL to 6.26 ± 1.93 ng/mL at p < 0.05, while P6 showed a decrease at 1 µg/mL to 6.93 ± 1.85 when compared to the LPS-induced inflammation (13.46 ± 0.52 ng/mL) at p < 0.05. In P7, TNF-α suppression was observed at both 1 and 10 µg/mL in 8.58 ± 0.84 and 7.62 ± 0.21 at p < 0.05, respectively. In contrast, P1 caused an increase in TNF-α production to 22.71 ± 0.93 at 0.1 µg/mL (Fig. 4a and c). For those obtained from trypsin digestion, T2 (8.72 ± 0.77, 7.06 ± 0.85, and 9.14 ± 1.41 ng/mL) and T6 (9.26 ± 0.34, 9.54 ± 0.29, and 8.21 ± 0.70 ng/mL) exhibited inhibitory activity against TNF-α levels across all concentrations (0.1–10 µg/mL) at p < 0.05 relative to their respective LPS induction (13.23 ± 2.23, 13.40 ± 1.09, and 11.89 ± 0.89 ng/mL). T7 also suppressed TNF-α release at 1 µg/mL (8.58 ± 0.44 ng/mL), while T4 (7.29 ± 0.43 ng/mL) and T1 (8.25 ± 0.28 ng/mL) at p < 0.05. While T8 significantly reduced at 0.1 and 1 µg/mL to 8.16 ± 0.43 and 6.98 ± 0.22 ng/mL, respectively at p < 0.05 (Fig. 4b and c). Effects of SDSP on LPS-induced pro-inflammatory cytokine releases. (a) TNF-α levels in cells treated with pepsin-digested peptides (P groups). (b) TNF-α levels in cells treated with trypsin-digested peptides (T groups). (c) Heat map of TNF-α levels in cells treated with SDSPs. *** p < 0.001 indicates a significant difference compared to the vehicle control group; # p < 0.05, ## p < 0.01, and ### p < 0.001 indicate significant differences compared to the LPS-challenged group. Treatment with SDSPs significantly reduced IL-6 secretion compared to the LPS-induced group (2.06 ± 0.02 ng/mL). Among the peptides, P7 showed a significant decrease in IL-6 levels at all tested concentrations (0.1–10 µg/mL) to 1.54 ± 0.04, 1.37 ± 0.03, and 1.40 ± 0.10 ng/mL at p < 0.05, respectively. P8 also suppressed IL-6 release at 1 and 10 µg/mL (1.14 ± 0.02 and 1.46 ± 0.07 ng/mL), whereas P1 exhibited a significant reduction only at 10 µg/mL (1.32 ± 0.02 ng/mL) at p < 0.05 (Fig. 5a and c). In the T groups, T6 significantly decreased IL-6 secretion at all tested concentrations (0.1–10 µg/mL) to 1.42 ± 0.22, 1.15 ± 0.93, and 1.18 ± 0.01, respectively, at p < 0.01 when compared to LPS exposure (2.16 ± 0.14). T7 and T8 also reduced IL-6 levels but only at 0.1 µg/mL and 1 µg/mL, yielding concentrations of 1.65 ± 0.09 and 1.71 ± 0.15 ng/mL, and 1.55 ± 0.09 and 1.44 ± 0.04 ng/mL (both p < 0.05), respectively (Fig. 5b and c). The full-length SDSP exhibited a consistent dose-dependent trend of decreasing both TNF-α and IL-6 levels, indicating broad anti-inflammatory potential across multiple cytokine pathways. Specifically, it reduced TNF-α concentrations to 11.05 ± 1.03, 10.90 ± 0.63, and 10.14 ± 0.80 ng/mL at 0.1, 1, and 10 µg/mL, respectively, compared to the LPS-induced group (13.60 ± 0.09 ng/mL). Similarly, IL-6 levels decreased to 1.79 ± 0.13, 1.58 ± 0.16, and 1.30 ± 0.10 ng/mL at the corresponding doses, relative to the LPS control (2.05 ± 0.05 ng/mL). Only the SDSPs that markedly decreased both TNF-α and IL-6 levels, without demonstrating cytotoxicity at any administered dosage, were chosen for further experimentation—specifically, T6, T7, T8, P7, and the full-length SLPI. Effects of SDSP on LPS-induced pro-inflammatory cytokine releases. (a) IL-6 levels in cells treated with pepsin-digested peptides (P groups). (b) IL-6 levels in cells treated with trypsin-digested peptides (T groups). (c) Heat map of IL-6 levels in cells treated with SDSPs. *** p < 0.001 indicates a significant difference compared to the vehicle control group; # p < 0.05, ## p < 0.01, and ### p < 0.001 indicate significant differences compared to the LPS-challenged group. Determination of intracellular ROS production In this study, intracellular ROS was determined using the DCFH-DA probe. Raw 264.7 exposed to 1 µg/mL of LPS for 24 h showed significant increases in relative percent fluorescence intensity to 176.46 ± 10.09% when compared to vehicle control (100.00 ± 7.95%). The pretreatment of certain SDSPs for 6 h before LPS exposure led to a reduction in ROS levels. Compared to LPS exposure, pretreatment with 0.1, 1, and 10 µg/mL of P7 led to a dose-dependent reduction in intracellular ROS levels to 135.55 ± 0.85%, 128.04 ± 8.30%, and 126.27 ± 3.71%, respectively at p < 0.05. T6 had a comparable pattern, decreasing ROS to 152.79 ± 12.49%, 127.04 ± 12.64%, and 127.21 ± 4.53%, respectively. T7 demonstrated reductions in ROS at concentrations of 0.1 and 1 µg/mL, yielding values of 116.83 ± 4.14% and 130.85 ± 2.93%, respectively, whereas T8 exhibited declines at concentrations of 1 µg/mL, resulting in values of 118.45 ± 12.32%. SLPI exhibited a decreasing trend, although the difference was not statistically significant (Fig. 6). Effects of SDSP on LPS-induced intracellular ROS production. *** p < 0.001 when compared to the vehicle-control group; # p < 0.05, ## p < 0.01, and ### p < 0.001 when compared to the LPS-challenged group. Effect of SDSPs on inflammatory signaling pathways This study conducted a Western blot analysis to examine the impact of SDSPs on inflammatory signaling pathways in accordance with these findings. In order to determine the optimal induction period, a time-course study was performed, as the expression of signaling proteins may fluctuate over time. The levels of key signaling proteins reached their maximum at 30 min post-induction after the cells were stimulated with LPS for 0, 0.5, 1, 2, 4, 6, 12, 18, and 24 h (Figure S1). Therefore, this condition was subsequently performed as the optimal time point for signaling pathway analysis. In RAW 264.7 cells, LPS stimulation activated the inflammatory response by increasing the phosphorylation of MAPK signaling proteins, including ERK, JNK, and p38. Moreover, both phosphorylated and total NF-κB protein levels increased after LPS treatment, demonstrating robust activation of the NF-κB signaling pathway. Figure 7a shows the Western blot protein bands of phospho and total protein in inflammatory signaling pathways. As a result, exposure to LPS increases p-ERK/ERK and p-ERK/𝛃-actin to 0.92 ± 0.03 and 0.78 ± 0.07 when compared to vehicle control (0.17 ± 0.01 and 0.13 ± 0.02), respectively, at p < 0.001. Pretreatment with T6 and T7 at 1 µg/mL significantly reduced the pERK/ERK ratio to 0.34 ± 0.01 and 0.61 ± 0.06, respectively, compared to the LPS-induced group (0.94 ± 0.03) at p < 0.01. Moreover, T8 significantly reduced ERK phosphorylation to 0.53 ± 0.03 and 0.66 ± 0.03 at 0.1 and 1 µg/mL, respectively. Similarly, P7 decreased the p-ERK/ERK ratio to 0.61 ± 0.07 and 0.57 ± 0.05, while the full-length SLPI exhibited the strongest inhibition, reducing the ratio to 0.54 ± 0.08 and 0.32 ± 0.05 at the corresponding concentrations (p < 0.01; Fig. 7b). Following the evaluation of phosphorylation and total protein changes, the ratios of p-ERK/β-actin and ERK/β-actin were also examined. Consistent with the p-ERK/ERK results, the p-ERK/β-actin ratio showed a similar decreasing trend (Fig. 7c). Although exposure to LPS did not alter total ERK expression, treatment with 0.1 and 1 µg/mL of T8, P7, and SLPI significantly decreased the ERK/β-actin ratio compared to the vehicle control (p < 0.05) (Fig. 7d). Effects of SDSPs on MAPK and NF-κB signaling pathways under LPS-induced inflammatory response. (a) Representative western blot bands. (b) p-ERK/ERK. (c) p-ERK/β-actin. (d) ERK/β-actin. (e) p-JNK/JNK. (f) p-JNK/β-actin. (g) JNK/β-actin. (h) p-p38/p38. (i) p-p38/β-actin. (j) p38/β-actin. (k) p-NF-κB/NF-κB. (l) p-NF-κB/β-actin. (m) NF-κB/β-actin. * p < 0.05, *** p < 0.001 vs. vehicle control group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. LPS-treated group. The Western blot images in panel (a) are cropped for clarity; full-length blots and experimental details are provided in Supplementary Original images of Blots and Figure S4-S7. LPS stimulation markedly increased JNK phosphorylation, as evidenced by elevated p-JNK/JNK and p-JNK/β-actin ratios of 1.27 ± 0.06 and 1.20 ± 0.07, respectively (p < 0.001), compared to the vehicle control (0.86 ± 0.04 and 0.73 ± 0.09). Conversely, the overall JNK levels did not change after exposure to LPS. Treatment with SDSPs resulted in a notable decrease in JNK phosphorylation. At a concentration of 0.1 µg/mL, the p-JNK/JNK ratios were recorded as follows: 0.93 ± 0.10 (T6), 0.98 ± 0.07 (T7), 0.72 ± 0.10 (T8), 0.73 ± 0.09 (P7), and 0.73 ± 0.05 (SLPI). These values were in contrast to the LPS-stimulated group, which had a ratio of 1.27 ± 0.06. At a concentration of 1 µg/mL, inhibition was observed, with the following ratios recorded: 0.77 ± 0.08 (T6), 0.82 ± 0.07 (T7), 0.66 ± 0.08 (T8), 0.70 ± 0.13 (P7), and 0.76 ± 0.16 (SLPI) (p < 0.01, Fig. 7e). In line with these findings, the p-JNK/β-actin ratios also demonstrated a similar pattern of decrease following SDSP and SLPI treatments (Fig. 7f). In terms of total protein expression, treatment with 1 µg/mL of T7 significantly reduced the JNK/β-actin ratio compared to the vehicle control. Similarly, both T8 and P7 treatments at concentrations of 0.1 and 1 µg/mL led to notable decreases in the JNK/β-actin ratio (p < 0.05; Fig. 7g). Similar to ERK and JNK, p38 MAPK was also markedly activated following LPS stimulation. The phosphorylation levels of p38 increased significantly, as shown by elevated p-p38/p38 and p-p38/β-actin ratios (0.99 ± 0.08 and 0.94 ± 0.09, respectively) compared with the vehicle control (0.11 ± 0.06 and 0.11 ± 0.05). Treatment with SDSPs attenuated p38 phosphorylation. In particular, T6 and T7 lowered the p-p38/p38 ratio from 1 µg/mL to 0.44 ± 0.11 and 0.54 ± 0.011, respectively. In contrast, T8, P7, and SLPI exhibited stronger inhibition, significantly reducing p38 phosphorylation at both 0.1 and 1 µg/mL to 0.63 ± 0.11 and 0.58 ± 0.07 (T8), 0.37 ± 0.05 and 0.31 ± 0.06 (P7), and 0.40 ± 0.10 and 0.24 ± 0.02 (SLPI), respectively, when compared to the LPS-induced group (0.99 ± 0.08) (Fig. 7h). A similar trend was observed for the p-p38/β-actin ratio, indicating that SDSPs effectively suppress LPS-induced p38 activation (Fig. 7i). LPS stimulation did not alter total p38 protein levels compared with the vehicle control. However, treatment with T8 and P7 at 0.1 and 1 µg/mL reduced the p38/β-actin ratio, while SLPI decreased at 1 µg/mL (Fig. 7j). Since MAPK activation can trigger downstream transcription factor NF-κB, a key inflammatory cell signaling pathway, then next examined the effect of SDSPs on NF-κB activation in RAW 264.7 cells under stimulated inflammation. LPS stimulation markedly increased NF-κB phosphorylation, as reflected by elevated p-NF-κB/NF-κB and p-NF-κB/β-actin ratios to 0.53 ± 0.06 and 0.96 ± 0.15, respectively (p < 0.001) when compared to vehicle control (0.19 ± 0.06 and 0.41 ± 0.07). Interestingly, total NF-κB levels were also elevated after LPS treatment, with NF-κB/β-actin significantly increasing to 0.87 ± 0.01 when compared to the control (0.61 ± 0.02), which means that LPS may activate NF-κB by phosphorylation and increase its overall protein expression. Treatment with SDSPs effectively attenuated NF-κB activation in RAW 264.7 cells. Specifically, p-NF-κB/NF-κB ratios were significantly decreased by T6 at 0.1 µg/mL (0.03 ± 0.04) and SLPI at 0.1 µg/mL (0.27 ± 0.07) at p < 0.05. In addition, T7, T8, and P7 significantly reduced the ratio at both 0.1 and 1 µg/mL to 0.29 ± 0.03 and 0.25 ± 0.02 (T7), 0.22 ± 0.03 and 0.17 ± 0.01 (T8), and 0.18 ± 0.05 and 0.16 ± 0.04 (P7), respectively (p < 0.01) when compared to LPS-stimulation (0.53 ± 0.06) (Fig. 7k). A similar trend was observed for the p-NF-κB/β-actin ratio (Fig. 7l). In contrast to the MAPKs, total NF-κB/β-actin levels were significantly elevated following LPS stimulation compared with the vehicle control. Treatment with T6, T7, T8, and P7 significantly reduced total NF-κB at both 0.1 and 1 µg/mL, respectively (p < 0.001), indicating that these SDSPs can partially normalize LPS-induced NF-κB expression (Fig. 7m). Cytotoxicity of potential SDSPs on cells representing vital organs Exposure of non-toxic dose for immune cells of SDSPs (Fig. 2), also show no cytotoxic in cell line representing various vital organs, including BEAS-2B (lung), EA.hy926 (endothelial), and BJS5TA (skin), AC16 (heart), HEK293t (kidney), and HEPG2 (liver) for 24 h compared to the vehicle control. (Fig. 8). Cytotoxic effects of selected SDSPs on vital organ–derived cell lines. (a) BEAS-2B (lung epithelial cells), (b) EA.hy926 (vascular endothelial cells), (c) BJ-5TA (skin fibroblasts), (d) AC16 (cardiac cells), (e) HEK293T (renal epithelial cells), and (f) HepG2 (hepatic cells). Cell viability was assessed after 24 h of SDSPs treatment using the MTT assay. Discussion When the body is infected or injured, inflammatory responses protect and heal tissue. However, an excessive, prolonged, or dysregulated inflammatory response can lead to low-grade inflammation, which is implicated in the development of various diseases18. ROS play a key role in infection clearance and inflammatory response. Uncontrolled ROS, can increase the phosphorylation of MAPKs to activate key inflammatory factors; the NF-κB transcription factor produces excessive pro-inflammatory cytokines, such as TNF-α and IL-619. To study inflammation in vitro, LPS-stimulated RAW 264.7 macrophages are widely used, as they reliably reproduce the ROS–MAPK–NF-κB–cytokine cascade20. In the present study, the inflammatory response model was optimized through preliminary dose evaluation, and 1 µg/mL LPS was selected as the optimal concentration, as it achieved a stationary maximal effect of inflammatory induction without causing toxicity to RAW 264.7 cells. This selection is consistent with previous research and facilitates comparability across studies21,22. Using this optimized inflammation model, we subsequently assessed the peptides’ effects to determine their retention of biological activity. Previous work showed that the full-length SLPI exhibited multiple biological effects, including modest anti-inflammatory activity alongside other functional traits10. However, the peptide showed certain limitations, such as susceptibility to proteolytic degradation, a short half-life, and low penetration into target cells. Given these findings, we designed a shorter peptide from SLPI to maintain its beneficial actions. Pepsin and trypsin were selected for the enzymatic cleavage of SLPI into SDSPs because they are key human proteases23. Previous research has demonstrated that the enzymatic digestion can yield short bioactive peptides with anti-inflammatory effects, thereby affirming their significance in the production of functionally active fragments24. Computational enzymatic digestion and analysis of SDSPs exhibited diverse physicochemical characteristics, including differences in hydrophobicity, charge, stability, protein-binding potential, and anti-inflammatory potential (AIP). The interaction between peptides and cell membranes is a major factor in both therapeutic efficacy and off-target toxicity. Full-length SLPI is characterized by a strong net positive charge (+ 10.30) and high hydrophobicity (26.05). These make it strongly attract negatively charged microbial surfaces or inflamed host cells25. However, these characteristics and their large size are related to toxic and haemolytic activity (53%), suggesting non-specific membrane damage. In silico fragmentation of SLPI into SDSPs allows for “functional refinement.” All of these cleaved fragments possess lower net charges and hydrophobicity compared to the parent protein. Although such fragmentation might decrease cellular attachment and membrane-interface interaction, it increases safety by reducing non-specific membrane damage and cell toxicity, as evidenced by the improved haemolytic profiles. Moreover, the smaller SDSPs (< 30 aa) offset decreased charges with improved diffusion kinetics and less steric hindrance26, enabling them to navigate biological barriers and access intracellular destinations more effectively than the larger full-length precursor (132 aa). The protein-binding potential (Boman Index) estimates a peptide’s tendency to interact with protein targets. While SLPI has a moderate Boman Index (1.25), some SDSPs have higher interaction potential. These might be some important parts of the peptide, typically hidden inside its structure. Peptides with higher Boman indices may interact more efficiently with inflammatory mediators or receptors, contributing to anti-inflammatory effects, whereas intermediate values indicate a compromise between effectiveness and selectivity27. GRAVY scores suggest a shift toward hydrophilicity. Similar to SLPI, most of SDSPs exhibit negative scores that facilitate enhanced solubility in watery environments like blood or cytoplasm. A few sections, such T1 and T8, have positive GRAVY scores. This high hydropathicity predicts poor solubility in water-based buffers, nonetheless hydrophobic habits frequently imply specific functional roles, such as membrane anchoring or deep lipid bilayer insertion to influence intracellular signaling28. The predicted stability of the SLPI and SDSPs is closely associated with their instability and aliphatic index. While full-length SLPI exhibits an Instability Index near the stability threshold (≈ 40), some SDSPs are predicted to be either more stable (< 40) or less stable (> 40) than the full-length protein. This suggests that in silico cleavage fragments may either increase or decrease overall stability compared to SLPI, thereby confirming that alterations in SDSPs can substantially affect protein stability. The aliphatic index was used to predict the thermostability of peptides via aliphatic side chains Ala, Val, Leu, and Ile, which are known to enhance structural stability at elevated temperatures. The full-length SLPI demonstrates moderate predicted thermostability. The in silico enzymatic cleavage strategy found fragments with a high aliphatic index. This indicates the enhancement of thermal resistance compared to the parent protein. However, some SDSPs lack aliphatic side chains, leading to a diminished predicted resistance to thermal unfolding. The findings suggest that the stability and thermostability of peptides are dependent on their sequences. The mentioned physiological characteristic might not accurately indicate the anti-inflammatory properties of the peptide; hence, it is necessary to predict the Anti-Inflammatory Potential (AIP). The AIP prediction assesses the probability of each peptide demonstrating anti-inflammatory action by an efficient computational predictor for identifying potential AIPs. This approach estimates the anti-inflammatory activity through machine and deep learning algorithms trained on sequence-based, structural, and physicochemical features29.. Among SDSPs, P4 (0.6558), P7 (0.6674), and P10 (0.7023) showed high AIP score than SLPI (0.5814) which might be a greater predicted anti-inflammatory potential. Short peptides may not form stable tertiary structures in solution, but their folded conformations can reveal physiologically important features. SDSPs found different structural characteristics, such as α-helical and loop-like arrangements, which are typical of bioactive peptides. Previous studies reported that AIP prediction correlates with anti-inflammatory activity of bioactive peptide30. Therefore, these SDSPs might have anti-inflammatory potential related to AIP score. Although, in silico predictions suggested the functional refinement through structure-activity relationships and action targets of SDSPs regarding cell membrane interaction, toxicity, and AIP scores. However, computational predictions cannot fully replicate the complexity of biological systems. Therefore, in vitro experimental validation must be required to confirm the predicted anti-inflammatory efficacy and safety of these SDSPs. To verify this prediction, the toxicity of SDSPs and their effects on the release of proinflammatory cytokines were tested. No toxic effects of SDSPs were observed at concentrations below 10 µg/mL except for P4, T1, T7, and T8, which their toxic dose were excluded to this study. Higher concentrations of some peptides may trigger cytotoxic effects on mammalian cells by compromising the cell membrane, resulting in cell lysis, or by triggering programmed cell death (apoptosis) through pathways such as mitochondrial dysfunction31. The anti-inflammatory effects of SDSPs at various concentrations were evaluated by measuring TNF-α and IL-6 levels. Several peptides significantly reduced TNF-α release, while a subset al.so suppressed IL-6 production. The differential in TNF-α and IL-6 suppression by SDSPs might be due to changes in cytokine regulation, kinetics, and peptide selectivity18. TNF-α is highly susceptible to peptides that inhibit the NF-κB and MAPK signaling pathways as an early response32. In contrast, IL-6 expression can be influenced by different mechanisms and reaches its maximum at a later time than TNF-α33. A peptide that reduces TNF-α may not completely suppress IL-6 if alternate signaling pathways are active or IL-6 kinetics differ from the measuring time point34. Consequently, in this investigation, we only chose the best SDSPs that inhibit the fluency of both TNF-α and IL-6, similar to full-length SLPI, to examine the inflammatory mechanism. Despite SDSPs, such as T6, T7, T8, and P7, exhibiting anti-inflammatory efficacy related to their AIP scores, other peptides (Such as P4, P5, P10, and T9) with comparable high AIP values did not exhibit significant suppression in the experimental study. Divergence between in silico predictions and biological outcomes in peptide research is attributed to pharmacokinetic and stability characteristics like enzymatic degradation and poor bioavailability35. AIP prediction models predominantly rely on primary sequence features without incorporating analysis of more complex structural or dynamic aspects that are essential to in situ function29,36. Although Machine-learning technologies are improving37, but neglecting structural restrictions and the multifactorial nature of inflammation limits their sensitivity, specificity, data quality, biological interpretability, and application to functional cellular settings38. These indicate that AIP scores serve as a screening filter but not fully definitive indicators of efficacy. Therefore, this gap is likely attributable to the constraints of in silico AIP predictions, which assess anti-inflammatory potential based on peptide sequence characteristics that require experimental validation. ROS serves as a crucial mediator of inflammation. Exposure to a hazardous element or LPS leads to the overproduction of intracellular ROS or oxidative stress. The accumulation of these highly reactive molecules initiates the activation of MAPK pathways. Activation of ERK, p38, and JNK stimulates the pivotal inflammatory transcription factor NF-κB to translocate into the nucleus, resulting in the production and release of pro-inflammatory cytokines, as described by multiple studies39. This study demonstrates that the LPS-induced macrophage inflammatory response similarly elevates ROS, MAPK, and NF-κB levels, which correlates with the reassessment of IL-6 and TNF-α. Selected SDSPs (T6, T7, T8, and P7) decrease intracellular ROS production, similar to SLPI. This full-length peptide exerts reduce ROS protect against non-communicable diseases (NCDs)10. The beneficial effect of SDSPs in diminishing excessive ROS generation may indicate that they are antioxidant peptides (AOPs), most of which have been shown to possess anti-inflammatory properties and to mitigate various disease risks40. Thus, these SDSPs have an anti-inflammatory effect related to oxidative stress. Cell signaling pathways play an important role in cellular mechanisms regulating inflammatory responses. Activation of the MAPK signaling cascade is a key step in inflammatory responses. It can activate proinflammatory cytokines such as TNF-α and IL-6 via crosstalk of NF-κB signaling41. Candidate SDSPs decrease the phosphorylation of ERK, p38, and JNK on LPS-induced macrophage cell inflammatory response. Reducing MAPK lowers inflammatory sensing and NF-κB phosphorylation via crosstalk. These findings are represented in our results, which show that these SDSPs also reduce the activation of NF-κB. Interestingly, treatment with these SDSPs led to a reduction in both phosphorylated and total forms of ERK, p38, and JNK. Inhibition of these forms of MAPK, resulting in a reduction in overall expression in comparison to their housekeeping protein. The extended treatment duration of these peptides may have facilitated the observed reduction by promoting feedback inhibition of MAPK synthesis42,43 or enhancing protein turnover44,45. Such an effect implies that T6, T7, T8, and P7 exert a more sustained regulatory influence on inflammatory signaling, beyond the transient inhibition of phosphorylation typically seen in early responses. Additionally, the rise in phosphorylated NF-κB reflects its activation and nuclear translocation, while the elevated total NF-κB suggests enhanced synthesis of the protein as part of a positive feedback mechanism to sustain the inflammatory response. This pattern is consistent with typical macrophage activation, where LPS stimulates both NF-κB activation and transcriptional upregulation to amplify proinflammatory gene expression46. T6, T7, T8, and P7 reduce both the phosphorylation and expression of NF-κB in LPS-induced macrophages. This finding suggests that these peptides reduce NF-κB signaling by regulating activation and downregulating its synthesis or expression. This dual inhibition may be responsible for the significant decrease in proinflammatory cytokines, suggesting that SDSPs appear to attenuate excessive inflammatory signaling caused by LPS stimulation. In contrast, SLPI primarily reduced phosphorylation without affecting total protein levels. This result indicates that SDSPs may have a more pronounced inhibitory effect on inflammatory signaling through the dual inhibition of phosphorylation and expression of MAPK and NF-κB, resulting in a reduction of proinflammatory cytokines and intracellular ROS. These data indicate that SDSPs, might promising candidates for anti-inflammatory agents, functioning as AIPs and AOPs via antioxidant activity and the inhibition of critical signaling pathways47. The anti-inflammatory activity of SDSPs appears to be closely associated with their physicochemical characteristics, such as moderate cationicity, balanced hydrophobicity, and short peptide length, from a structure–activity perspective of these AIPs and AOPs. The presence of positively charged residues may enhance electrostatic interactions with negatively charged cellular membranes and Toll-like receptor 4 (TLR4)-associated signaling complexes, potentially disrupting early adaptor recruitment and downstream kinase activation. Controlled hydrophobicity may enhance membrane penetration and intracellular accessibility while avoiding cytotoxic effects. Their short length and structural flexibility may help to penetrate the cell and facilitate interactions with intracellular signaling mediators, thereby enabling modulation of MAPK/NF-κB pathways. Short peptide fragments may demonstrate unique functional advantages when compared to full-length SLPI. Intact SLPI is vulnerable to proteolytic degradation by both extracellular and intracellular proteases, such as matrix metalloproteinases (MMPs), especially in inflammatory conditions. Selected SDSPs may exhibit modified susceptibility to enzymatic cleavage as a result of their simplified structure and optimized residue composition, which could enhance stability in inflammatory microenvironments. Furthermore, their smaller molecular size may enhance cellular uptake, enabling direct elimination of intracellular ROS accumulation and interaction with redox-sensitive signaling components. This intracellular activity may play a role in the coordinated suppression of ROS, MAPK phosphorylation, and NF-κB activation noted in this study. The identification of various active peptides via computational enzymatic cleavage indicates that SLPI exhibits multiple cryptic immunomodulatory domains within its native structure. In the intact protein, these domains might show structural constraints or be primarily linked to protease inhibitory functions. Upon fragmentation, discrete peptide segments may exhibit independent biological activities, thereby supporting the suggestion that endogenous proteins can function as reservoirs of latent therapeutic peptides. The systematic identification of bioactive short fragments via in silico enzymatic simulation, coupled with experimental validation, represents an effective approach for peptide drug discovery. This approach emphasizes fragments with optimal charge, hydrophobic balance, and predicted bioactivity, thereby enabling the creation of structurally simplified peptide therapeutics that exhibit improved specificity, reduced toxicity risk, and greater translational potential. SDSPs no cytotoxic in cardiomyocytes, lung, endothelial, fibroblasts, hepatocytes, and kidney vital organ cell lines. These findings suggest that SDSPs exhibit a favourable safety profile in vitro, indicating their potential for further development as anti-inflammatory agents. The observed low cytotoxicity may relate to the moderate cationicity and balanced hydrophobicity of these compounds, facilitating membrane interaction while avoiding destabilization or lytic effects often observed with highly cationic or amphipathic peptides. The selected SDSPs, in contrast with highly membrane-disruptive antimicrobial peptides, exhibit neither excessive positive charge nor extreme hydrophobicity, thereby minimizing the risk of nonspecific membrane damage or mitochondrial dysfunction. The selection process for peptides moving into mechanistic studies was based on those that markedly without demonstrating cytotoxicity or pro-inflammatory effects at any administered dosage. This finding suggests that T6, T7, T8, and P7 are candidates from this study, possessing a superior therapeutic window, maintaining high anti-inflammatory and antioxidant efficacy at concentrations that remain entirely non-toxic to healthy host tissues. In summary, the findings in this study support the potential anti-inflammatory activity of SDSPs in LPS-stimulated macrophages. The observed reduction in intracellular ROS may contribute to the attenuation of the MAPK/NF-κB signaling cascade, resulting in a decline in the production of inflammatory cytokines (TNF-α and IL-6). This, in turn, reduces inflammation (Fig. 9). Although these findings imply that candidate SDSPs possess advantages in reducing inflammation in this particular in vitro model, these interpretations remain a mechanistic hypothesis that requires further experimental verification. Furthermore, although SDSPs exhibit potential as AIPs, further in vivo studies and clinical trials are required to determine their pharmacokinetic properties, safety profile, and therapeutic efficacy. Graphical representation of the proposed mechanism of candidate SDSPs anti-inflammation on macrophages induced by LPS. Created in BioRender.com. There are several limitations that should be acknowledged in this study. While in silico models offer a cost-effective screening strategy, a notable divergence was observed between computational predictions and experimental outcomes, as high AIP scores did not consistently correlate with in vitro cytokine suppression. This discrepancy highlights the current algorithms’ reliance on primary sequence features rather than complex structural dynamics, positioning computational scores as preliminary screening tools rather than definitive indicators of efficacy. Furthermore, the use of an in vitro LPS-stimulated RAW 264.7 macrophage model, while standard for studying fundamental mechanisms, fails to capture the systemic complexity of multicellular immune responses, tissue-specific microenvironments, or the progression of chronic inflammatory diseases. Although the suppression of MAPK and NF-κB provides mechanistic evidence for anti-inflammatory activity, other critical pathways—such as oxidative stress regulation and inflammasome activation—remain unexplored, and the absence of genetic or pharmacological validation (e.g., targeted knockouts) limits the identification of causal mechanisms. Furthermore, the development of SLPI-derived short peptides (SDSPs) was specifically driven by the intrinsic limitations of full-length SLPI, particularly its brief half-life and diminished cellular uptake; however, the extent to which these smaller fragments address these challenges in a systemic context has yet to be thoroughly clarified. Theoretically, the reduced molecular size of SDSPs should improve diffusion kinetics and enable superior traversal of biological obstacles compared to the full-length SLPI precursor. It is crucial to recognise that in vitro efficacy does not invariably forecast in vivo stability. Within a complete organism, these peptides encounter a multifaceted environment of circulating proteases, swift renal clearance, and possible binding by plasma proteins, all of which may influence their therapeutic half-life. In addition, the assessment of cytotoxicity in cell lines representing essential organs—namely the lung (BEAS-2B), heart (AC16), liver (HepG2), and kidney (HEK293T)—establishes a fundamental safety profile. However, these static cell culture models are incapable of mimicking the complex pharmacodynamics and multicellular immunological responses found in a living organism. Consequently, subsequent in vivo validation is essential to evaluate pharmacokinetic profiles, long-term safety, and the potential of advanced delivery systems to bridge the gap between these experimental findings and viable therapeutic applications. Conclusion Candidate SDSPs are effective in mitigating inflammation in LPS-induced macrophages by decreasing intracellular ROS levels and the MAPK and NF-κB signaling pathways, which lowers the production and release of pro-inflammatory cytokines like TNF-α and IL-6. These findings suggest that SDSPs may help protect cells from inflammation-induced injury in this in vitro model. Thus, SDSPs show potential to act as AIPs and AOPs. These SDSPs represent promising candidates for the development of peptide-based strategies targeting inflammation-related conditions, for which further in vivo studies and functional mechanistic investigations are required to validate their therapeutic potential. Method and material Chemicals The chemicals used in this study were analytical grade or higher (≥ 95%) obtained from Sigma-Aldrich (St. Louis, MO, USA). Type 1 ultrapure water was obtained using the Smart2Pure™ Water Purification System (Thermo Fisher Scientific, Waltham, MA, USA), with a resistivity of 18.2 MΩ·cm at 25 ◦C and a Total Organic Carbon (TOC) level of ≤ 10 ppb. Bio-Rad protein assay and polyacrylamide were obtained from Bio-Rad Laboratories Ltd. Cell cultures, including Dulbecco’s Modified Eagle Medium (DMEM), foetal bovine serum (FBS), trypsin–EDTA solution, (3-(4,5-dimethylthiazolyl-2)−2, 5-diphenyltetrazolium bromide) (MTT), 2′,7′-dichlorofluorescein diacetate (DCFH-DA), and cell culture supplies (dishes, plates, and others), were obtained from Gibco® (Thermo Fisher Scientific, Waltham, MA, USA). SDSPs’ preparation, structure, and characteristic prediction SDSP sequences were predicted in silico using the PeptideCutter tool, Peptide characterization software from ExPASy (https://web.expasy.org/peptide_cutter/). Briefly, full-length SLPI p03973 (https://www.uniprot.org/uniprotkb/P03973/entry) was digested virtually using pepsin and trypsin. The cleavage fragments were listed according to their position of cleavage sites and peptides shorter than five amino acids were excluded from further analysis because fragments such as dipeptides, tripeptides, and tetrapeptides are typically deemed unsuitable for evaluation in drug discovery due to their suboptimal pharmacological characteristics, significant instability, and insufficient specificity. This ensures sufficient side-chain variety for forming stable molecular interactions and indicates unique functional motifs. This procedure yielded 21 SDSPs: eleven derived from pepsin digestion (P group), nine from trypsin digestion (T group), and one from the N-terminal region (MKSSGLFPFLVLLALGTLAPWAVEGSGKSFKAGVCPPKKSAQCLRYKKPEC (51 amino acids)). The selected SDSPs were custom-synthesized by the Fmoc-solid phase synthetic method (GL Biochem, Shanghai, People’s Republic of China) with a purity above 95%. The quality control was verified by the manufacturer via high-performance liquid chromatography and mass spectrometry. The lyophilized powders were dissolved according to the manufacturer’s recommendations, and stock solutions (1 mg/mL) were stored at − 80 °C until use in experiments. The physicochemical properties of the SDSPs, including peptide mass, molecular formula, Wimley-White whole-residue hydrophobicity, protein-binding potential (Boman index), and grand average of hydropathicity (GRAVY), were evaluated using the Antimicrobial Peptide Calculator and Predictor (https://aps.unmc.edu/prediction). Theoretical pI, aliphatic index, and instability index were computed using ProtParam from Expasy (https://web.expasy.org/protparam/), while net charge at pH 7.4 was determined using the Biosynth Peptide Calculator (https://www.biosynth.com/peptide-calculator). Predictions of haemolytic activity, solubility, and nonfouling properties were performed using peptides.bio v0.19.0 (https://peptide.bio/). The anti-inflammation prediction (AIP) was evaluated by the server AIPpred29(http://www.thegleelab.org/AIPpred/). The three-dimensional structures of the SDSPs were modelled using OpenProtein.AI (https://www.openprotein.ai/), a platform leveraging protein language models and the BOLTZ2 and AlphaFold2 algorithms. Cell culture and treatment Murine macrophage cells, RAW 264.7, obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA), were used to investigate the anti-inflammatory potential of SDSPs. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 100 units/mL of penicillin and 100 µg/mL of streptomycin within the Eppendorf CellXpert C170i Cell Culture CO₂ Incubator (Eppendorf, Hamburg, Germany), maintained at 37 °C under a humidified atmosphere of 5% (v/v) CO₂. The culture media were refreshed every two to three days, and cells were subcultured for experimentation after reaching 80–90% confluence. For the treatment, cells were pre-induced with SDSPs at various concentrations from 0.1 to 10 µg/mL for 6 h. Following washing with PBS, inflammation occurred by adding fresh media containing 1 µg/mL lipopolysaccharide (LPS) for 24 h. After treatment, cells were processed according to the experimental procedure. Determination of LPS and SDSPs toxicity The 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the effect of LPS and SDSPs on cell viability. Briefly, cells at a density of 1 × 10^4 cells per well were seeded in a 96-well cell culture plate for 18–24 h. Subsequently, fresh media containing 0.001–100 µg/mL of LPS from Escherichia coli O111:B4 (Sigma-Aldrich, St. Louis, MO, USA) or 0.1–10 µg/mL of SDSPs were added and incubated for 24 h. To assess cytotoxicity, cells were washed with 1× PBS and subsequently incubated in DMEM with 0.25 mg/mL MTT for 3 h. Following incubation, the media were discarded, and the resulting formazan crystals were solubilized in 100% DMSO. The plate was agitated for 10 min, and the absorbance was measured at 550 nm using a microplate reader (Infinite M200 PRO, Tecan, Männedorf, Switzerland). Both the full-length SLPI and its N-terminal fragment were evaluated under the same experimental conditions as the other SDSPs. Cell viability was expressed as the percentage of viable cells relative to untreated controls. Assessment of SDSPs on LPS-Induced IL-6 and TNF-ɑ Release Establishment of the LPS-Induced Inflammation Model To determine the optimal LPS concentration for cytokine induction, RAW 264.7 cells were stimulated with various concentrations of LPS (0.001–100 µg/mL) for 24 h. Culture media were collected, and the levels of IL-6 and TNF-α were quantified using murine IL-6 (#900-T50K) and TNF-α (#900-T54K) ELISA Development Kits (PeproTech®, Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instructions. Briefly, samples and standards were added to antibody-coated plates and washed four times with wash buffer. Plates were blocked for 1 h, incubated with biotinylated anti-IL-6 or anti-TNF-α for 2 h, washed, and then treated with streptavidin-HRP for 30 min. Colour was developed using TMB substrate, and absorbance was measured at 450 nm with a reference at 620 nm using a microplate reader (Infinite M200 PRO, Tecan, Männedorf, Switzerland). The LPS concentration that induced significant cytokine release without causing cytotoxicity was selected for subsequent experiments. Evaluation of the preventive effect of SDSPs To evaluate the impact of SDSPs on the release of inflammatory cytokines. Cells were pretreated with SDSPs at concentrations ranging from 0.1 to 10 µg/mL for 6 h, thereafter activating the inflammatory response with 1 µg/mL of LPS for 24 h. After incubation, the conditioned media were collected, and IL-6 and TNF-α levels were measured using the same IL-6 and TNF-α ELISA Development Kits as described above. Determination of intracellular ROS The effects of SDSPs on LPS-induced intracellular ROS production and oxidative stress in RAW 264.7 were evaluated using the intracellular ROS probe 2′,7′-dichlorofluorescein diacetate (DCFH-DA). Cells were seeded in a 96-well at a density of 1 × 104 cells/well in complete DMEM and cultured for 18–24 h. After removing the medium, cells were pretreated with SDSPs (0.1–10 µg/mL) for 6 h. Subsequently, cells were washed with 1× PBS and incubated with 1 µg/mL of LPS in DMEM for 24 h. After treatment, cells were washed with 1X PBS and incubated with medium containing 10 µM DCFH-DA for 30 min at 37 °C. Then the supernatant was removed, and the cells were washed twice with 1 x PBS. Intracellular ROS levels were measured using a microplate reader (Infinite M200 PRO, Tecan, Männedorf, Switzerland) with excitation and emission wavelengths of approximately 485 nm and 535 nm, respectively. Relative percent fluorescence intensity was expressed as the percentage of fluorescence intensity relative to the untreated control. Western blot assay RAW 264.7 cells were seeded in 35-mm culture dishes at a density of 2 × 10⁶ cells/dish and cultured for 18–24 h until reaching 80–90% confluency. Cells were then pretreated with SDSPs for 6 h, followed by stimulation with LPS. Since phosphorylation of signaling proteins occurs at different time points, cells were exposed to LPS for varying durations (0–24 h) to determine the optimal condition showing significant phosphorylation, which was subsequently selected for analysis. Cellular proteins were extracted using RIPA lysis buffer (Sigma-Aldrich, St. Louis, MO, USA). Protein concentrations were determined using the Bio-Rad Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Then, protein concentrations were normalized to ensure equal loading (20 µg per lane), and protein samples were separated on 10–12% SDS-PAGE and transferred to 0.45 μm PVDF membranes. The nonspecific protein-binding sites on blotted membranes were blocked for 1 h using a 5% (w/v) blocking solution of BSA or non-fat dried milk in tris-buffered saline with 0.1% (v/v) Tween® 20 detergent (TBST). Then membranes were subsequently incubated overnight with primary antibodies diluted to 1:1000 in blocking buffer. The primary antibodies included p-NF-κB (sc-136548), NF-κB (sc-8008), p38 (sc-7972), p-JNK (sc-6254), JNK (sc-7345), p-ERK (sc-81492), ERK (sc-514302), and β-actin (sc-81178) obtained from Santa Cruz Biotechnology (Bergheimer, Heidelberg, Germany), and p-p38 (9215s) obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). The probed membranes were washed twice with 1× TBST and incubated with 1:3000 anti-rabbit (#7076) or anti-mouse (#7074) IgG conjugated (Cell Signaling Technology, Danvers, Massachusetts, USA) with horseradish peroxidase (HRP) for 1 h after three rinsings (10 min each) with 10 mL of 1× TBST. The protein bands on the membranes were probed with Amersham ECL Western Blot Reagent and detected with an Amersham™ ImageQuant™ 800 Western blot imaging system (Cytiva, Marlborough, Massachusetts, United States) after a wash with 1× TBST. ImageJ software was employed to quantify and analyse the bands. Determination of in vitro cytotoxicity of SDSPs in vital organ representing cells To evaluate the potential applicability of SDSPs across different vital organs, additional cell lines obtained from ATCC were used, including AC16 (heart), BEAS-2B (lung), EA.hy926 (vascular endothelium), HEK293T (kidney), HepG2 (liver), and BJ-5ta (skin). Briefly, cells were placed into 96-well plates at a density of 1 × 10⁴ cells/well and cultivated in complete medium under standard conditions (37 °C, 5% CO₂). Various concentrations of SDSPs (0.1–10 µg/mL) were administered to cells for 24 h after they had reached approximately 70–80% confluence. The MTT assay was employed to evaluate cell viability, and the absorbance was measured at 570 nm using a microplate reader. The percentage of viability was indicated in relation to the untreated control cells. Statistical analysis The GraphPad Prism software (version 10) was employed to conduct the statistical analysis of this study. The results are presented as the mean ± SEM from at least three independent biological replicates (n ≥ 3). The dose–response data curves in the trials were analysed using linear and non-linear (curve fit) regressions. The one-way ANOVA by Tukey’s multiple comparisons test was employed to examine differences between various groups based on a single factor, while the two-way ANOVA followed by Tukey’s post hoc test was employed to assess the interaction and main effects of two independent variables. An unpaired Student’s t-test was employed to conduct comparisons between the two categories. Statistical significance was defined as a p-value that was less than 0.05. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors would like to thank the Biomedical Engineering and Innovation Research Centre, CMU-BIOPOLIS Building, Chiang Mai University, for providing facility support. The author acknowledges the use of AI to improve grammar and clarity. Author contributions Conceptualization, W.J., S.R., and S.K.; methodology, W.J., K.K., N.C., O.S., and K.B.; validation, W.J., K.K., and S.K.; formal analysis, W.J. and K.K.; investigation, W.J. and K.K.; resources, S.K.; data curation, W.J. and K.K.; writing—original draft preparation, W.J.; writing—review and editing, S.K.; visualization, W.J., K.K., and S.K.; supervision, S.K.; project administration, S.K.; funding acquisition, S.K. All authors have read and agreed to the published version of the manuscript. Funding This work was supported by the CMU Proactive Researcher Program, Chiang Mai University (Grant number EX010163) for W.J. This research was funded by the National Research Council of Thailand (NRCT), The National Research Council of Thailand (NRCT) for postgraduate research: N43A680318, for O.S. The present study was supported by the CMU Presidential Scholarship 2023 from Chiang Mai University for O.S. Data availability All datasets generated and/or analysed during this study, including the raw and processed Western blot data are available in the OSFHOME repository, [https://doi.org/10.17605/OSF.IO/PMFD9](https:/doi.org/10.17605/OSF.IO/PMFD9). Declarations Competing interests The authors declare no competing interests. Ethics declarations. This article does not contain any studies with human or animal participants. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All datasets generated and/or analysed during this study, including the raw and processed Western blot data are available in the OSFHOME repository, [https://doi.org/10.17605/OSF.IO/PMFD9](https:/doi.org/10.17605/OSF.IO/PMFD9).